How to buy Aquestive Therapeutics stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aquestive Therapeutics stock

Own Aquestive Therapeutics stock in just a few minutes.

Aquestive Therapeutics, Inc is a biotechnology business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Aquestive Therapeutics employs 187 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Aquestive Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aquestive Therapeutics. Find the stock by name or ticker symbol: AQST. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aquestive Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aquestive Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aquestive Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aquestive Therapeutics share price

Use our graph to track the performance of AQST stocks over time.

Aquestive Therapeutics shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$3.45 - USD$9.465
50-day moving average USD$4.8164
200-day moving average USD$5.5827
Wall St. target priceUSD$14.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.605

Buy Aquestive Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aquestive Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aquestive Therapeutics financials

Revenue TTM USD$45.8 million
Gross profit TTM USD$32.9 million
Return on assets TTM -37.93%
Return on equity TTM 0%
Profit margin -121.67%
Book value $-0.985
Market capitalisation USD$157.7 million

TTM: trailing 12 months

Shorting Aquestive Therapeutics shares

There are currently 2.8 million Aquestive Therapeutics shares held short by investors – that's known as Aquestive Therapeutics's "short interest". This figure is 15.6% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Aquestive Therapeutics shares can be evaluated.

Aquestive Therapeutics's "short interest ratio" (SIR)

Aquestive Therapeutics's "short interest ratio" (SIR) is the quantity of Aquestive Therapeutics shares currently shorted divided by the average quantity of Aquestive Therapeutics shares traded daily (recently around 975322.75862069). Aquestive Therapeutics's SIR currently stands at 2.9. In other words for every 100,000 Aquestive Therapeutics shares traded daily on the market, roughly 2900 shares are currently held short.

However Aquestive Therapeutics's short interest can also be evaluated against the total number of Aquestive Therapeutics shares, or, against the total number of tradable Aquestive Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aquestive Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Aquestive Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1341% of the tradable shares (for every 100,000 tradable Aquestive Therapeutics shares, roughly 134 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aquestive Therapeutics.

Find out more about how you can short Aquestive Therapeutics stock.

Aquestive Therapeutics share dividends

We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.

Aquestive Therapeutics share price volatility

Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $3.45 up to $9.465. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 3.7241. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aquestive Therapeutics overview

Aquestive Therapeutics, Inc. , a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site